Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism | Zendy

Gary E. Raskob | Zendy; Nick van Es | Zendy; Peter Verhamme | Zendy; Marc Carrier | Zendy; Marcello Di Nisio | Zendy; David García | Zendy; Michael Grosso | Zendy; Ajay K. Kakkar | Zendy; Michael J. Kovacs | Zendy; Michele Mercuri | Zendy; Guy Meyer | Zendy; Annelise Segers | Zendy; Minggao Shi | Zendy; TzuFei Wang | Zendy; Erik Yeo | Zendy; George Zhang | Zendy; Jeffrey I. Zwicker | Zendy; Jeffrey I. Weitz | Zendy; Harry R. Büller | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism

Author(s) -

Gary E. Raskob,

Nick van Es,

Peter Verhamme,

Marc Carrier,

Marcello Di Nisio,

David García,

Michael Grosso,

Ajay K. Kakkar,

Michael J. Kovacs,

Michele Mercuri,

Guy Meyer,

Annelise Segers,

Minggao Shi,

TzuFei Wang,

Erik Yeo,

George Zhang,

Jeffrey I. Zwicker,

Jeffrey I. Weitz,

Harry R. Büller

Publication year - 2017

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1711948

Subject(s) - edoxaban , venous thromboembolism , medicine , heparin , cancer , cancer treatment , intensive care medicine , low molecular weight heparin , anticoagulant , anticoagulant therapy , oncology , warfarin , thrombosis , rivaroxaban , atrial fibrillation

Low-molecular-weight heparin is the standard treatment for cancer-associated venous thromboembolism. The role of treatment with direct oral anticoagulant agents is unclear.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research